CA Patent

CA3104760C — Benzimidazole derivatives and use thereof as idh1 inhibitors

Assigned to KPC Pharmaceuticals Inc · Expires 2023-09-26 · 3y expired

What this patent protects

The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

USPTO Abstract

The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3104760C
Jurisdiction
CA
Classification
—
Expires
2023-09-26
Drug substance claim
No
Drug product claim
No
Assignee
KPC Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.